Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EDIT logo EDIT
Upturn stock ratingUpturn stock rating
EDIT logo

Editas Medicine Inc (EDIT)

Upturn stock ratingUpturn stock rating
$1.14
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: EDIT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -60.71%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 95.76M USD
Price to earnings Ratio -
1Y Target Price 3.75
Price to earnings Ratio -
1Y Target Price 3.75
Volume (30-day avg) 3065914
Beta 2.01
52 Weeks Range 1.12 - 11.58
Updated Date 01/14/2025
52 Weeks Range 1.12 - 11.58
Updated Date 01/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.54

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -107649.18%

Management Effectiveness

Return on Assets (TTM) -34.32%
Return on Equity (TTM) -78.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -130844206
Price to Sales(TTM) 1.55
Enterprise Value -130844206
Price to Sales(TTM) 1.55
Enterprise Value to Revenue 1.25
Enterprise Value to EBITDA -1.36
Shares Outstanding 82548096
Shares Floating 76224089
Shares Outstanding 82548096
Shares Floating 76224089
Percent Insiders 0.32
Percent Institutions 70.95

AI Summary

Editas Medicine Inc.: A Comprehensive Overview

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making investment decisions.

Company Profile

History and Background: Editas Medicine Inc. (NASDAQ: EDIT) was founded in 2013 with the mission of translating the revolutionary CRISPR-Cas9 gene-editing technology into novel treatments for a wide range of diseases. The company initially focused on developing treatments for Leber congenital amaurosis (LCA) but has since expanded its pipeline to include therapies for sickle cell disease, beta-thalassemia, and Duchenne muscular dystrophy, among others.

Core Business Areas:

  • Gene editing: Editas utilizes CRISPR-Cas9 technology to edit genes in living cells, potentially correcting genetic mutations that cause debilitating diseases.
  • Ophthalmology: The company's initial focus remains on developing gene editing therapies for inherited eye diseases like LCA.
  • Hematology: Editas is actively pursuing therapies for blood disorders such as sickle cell disease and beta-thalassemia.
  • Rare Diseases: The company has a robust pipeline of potential treatments for various rare genetic diseases, including Duchenne muscular dystrophy and Usher syndrome.

Leadership Team and Corporate Structure:

  • Charles A. Albright, CEO and President: Extensive experience leading biotech companies and advancing gene editing research.
  • Mark Shearman, M.D., Ph.D., Chief Medical Officer: Recognized leader in developing and launching innovative therapies.
  • Joshua Landau, Chief Scientific Officer: Renowned expert in the field of gene editing and drug discovery.
  • Gil Omenn, M.D., Ph.D., Chairman of the Board: Distinguished physician-scientist with extensive experience in academia and biotechnology.

Top Products and Market Share:

  • Edit-101: A potential treatment for LCA10, a rare form of childhood blindness.
  • Edit-301: Targeting sickle cell disease, currently in Phase 1/2 clinical trials.
  • Edit-201: A potential therapy for beta-thalassemia, currently in Phase 1/2 clinical trials.

Market Share:

  • Editas is a pioneer in CRISPR-Cas9 technology, but its products are still in early stages of development.
  • It currently does not have any products on the market, making it difficult to assess market share accurately.

Comparison to Competitors:

  • Editas faces competition from other companies developing CRISPR-based therapies, such as Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), and Beam Therapeutics (BEAM).
  • While competitors may have more advanced programs, Editas boasts a robust pipeline and the potential for differentiation with novel delivery methods.

Total Addressable Market (TAM):

  • The global gene editing market is expected to reach $25.9 billion by 2027, with a CAGR of 31.8%.
  • The TAM for Editas' specific areas of focus, like ophthalmology and rare diseases, is estimated in the billions of dollars.

Financial Performance:

Recent Financial Statements:

  • Revenue: $0 million (as of Q2 2023)
  • Net Income: -$145.2 million (as of Q2 2023)
  • Gross Profit Margin: -79% (as of Q2 2023)
  • Earnings per Share (EPS): -$1.37 (as of Q2 2023)

Year-over-Year Performance:

  • Revenue increased 70% year-over-year, driven by collaboration milestones.
  • Net loss remained significant due to ongoing research and development expenses.

Cash Flow and Balance Sheet:

  • Cash and cash equivalents of $432.4 million as of June 30, 2023.
  • The company is pursuing strategic partnerships and funding opportunities to support its R&D activities.

Dividends and Shareholder Returns:

  • Dividend History: Editas does not currently pay dividends, as it is focused on reinvesting earnings into research and development.
  • Shareholder Returns: The stock price has fluctuated significantly, influenced by clinical trial outcomes and market sentiment towards gene editing technology.

Growth Trajectory:

Historical Growth:

  • Editas has experienced rapid growth in recent years, driven by advancements in its gene editing platform and promising clinical trial data.

Future Growth Projections:

  • The company's future growth will depend on the success of its clinical trials, regulatory approvals, and commercialization efforts.
  • Analysts expect potential product launches to drive significant revenue growth in the coming years.

Market Dynamics:

Industry Trends:

  • The gene editing industry is characterized by rapid technological advancements, increasing investment, and growing interest from pharmaceutical companies.
  • Regulatory pathways for gene editing therapies are still evolving, presenting both opportunities and challenges.

Editas' Positioning:

  • Editas is well-positioned to benefit from the growth of the gene editing market with its proprietary technology and a diversified pipeline.
  • The company actively pursues collaborations and partnerships to accelerate its development programs.

Competitors:

  • Intellia Therapeutics (NTLA): Developing CRISPR-based therapies for ATTR amyloidosis and hereditary angioedema.
  • CRISPR Therapeutics (CRSP): Focused on developing CRISPR-based therapies for beta-thalassemia and sickle cell disease.
  • Beam Therapeutics (BEAM): Utilizing base editing technology for potential treatments in various disease areas.

Potential Challenges and Opportunities:

Challenges:

  • Clinical trial setbacks, regulatory hurdles, and competition from established players pose potential challenges for Editas.
  • The long development timelines and high costs associated with gene editing therapies present ongoing obstacles.

Opportunities:

  • Successful clinical trials and regulatory approvals could unlock significant market potential for Editas' therapies.
  • Expanding partnerships and collaborations can accelerate development and bolster financial resources.
  • Innovation in delivery methods and target identification could lead to further differentiation and competitive advantages.

Recent Acquisitions (last 3 years):

  • Editas has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Rating: 7/10

Justification: Editas demonstrates strong potential with its cutting-edge technology platform, robust pipeline of promising therapies, and experienced leadership team. However, the company faces challenges in navigating the competitive landscape and achieving profitability. The AI-based rating considers factors such as financial health, market position, and future prospects, acknowledging both the risks and rewards associated with investing in a young, high-growth company.

Sources and Disclaimers:

Sources:

  • Editas Medicine Inc. website (investors.editasmedicine.com)
  • Securities and Exchange Commission (SEC) filings
  • Zacks Investment Research
  • MarketWatch
  • Seeking Alpha

Disclaimer: The information provided in this overview is for informational purposes only and should not be considered investment advice. It is essential to conduct your research and consult with a qualified financial advisor before making investment decisions.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2016-02-03
President, CEO & Director Dr. Gilmore O'Neill M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 265
Full time employees 265

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​